Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study

NCT02226757 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT02226757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02226757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2014
Completion date
Not reported
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr-mutation, her2-expression, nsclc